Gut microbiota alterations in myelodysplastic neoplasms are associated with immune dysfunction and the mechanism of hypomethylating agent treatment (PRJCA039399)
Myelodysplastic neoplasms (MDS) are heterogeneous clonal disorders and immune dysregulation contributes to its pathogenesis. Dysbiosis of gut microbiota has been reported to play a critical role in regulating the immune system. We aimed to compare the gut microbiota compositions and functions between MDS patients and healthy controls (HC) as well as after hypomethylating agent (HMA) treatment.